Y2R antagonists inhibited tumor growth and NPY-induced angiogenesis in colorectal cancer [121], and the Y2R antagonist BIIE0246 decreased melanoma tumor weight, angiogenesis, and serum VEGF level [171]. The gene discussed is NPY; the disease is neoplasm.